OLIGOMER COMPOUND REDUCING EXPRESSION OF HUMAN GENE Bcl-2, CONJUGATE, PHARMACEUTICAL COMPOSITION AND APPLICATION OF OLIGOMER COMPOUND IN CANCER TREATMENT Russian patent published in 2009 - IPC C12N15/11 A61K31/7088 

Abstract RU 2377301 C2

FIELD: pharmacology.

SUBSTANCE: invention concerns biotechnology, specifically to oligomer compound of length 10-30 nucleic bases, and can be used in medicine. The oligomer compound represents a target-binding domain complementary to a segment of 10-18 sequential nucleotides of the region including base position 1459 (5') to 1476 (3') human mRNA Bcl-2 (HUMBcl2A (approach number M13994) in database GenBank), except maximum one inaccurate coupling with specified site of human mRNA Bcl-2 where said target-binding domain is described by formula: 5' - [(DNA/RNA)0-1-(LNA/LNA*)2-7-(DNA/RNA/LNA*)4-14-(LNA/LNA*)2-7-(DNA/RNA)0-1]-3'.

EFFECT: oligomer compound effectively reducing expression of human gene Bcl-2.

25 cl, 20 dwg, 3 tbl, 16 ex

Similar patents RU2377301C2

Title Year Author Number
COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF DYSTROPHIC MIOTONIN-PROTEINKINASE (DMPK) 2014
  • Pandey Sanjay K.
  • Macleod Robert A.
  • Swayze Eric E.
  • Bennett C. Frank
RU2690333C2
FACTOR 11 EXPRESSION MODULATION 2009
  • Frejer S'Juzan M.
  • Monija Brett P.
  • Chzhan Khun
  • Chzhao Chehn'Guan
  • Krosbi Dzheffri R.
  • Sivkovski Ehndrju M.
RU2535964C2
MODULATION OF FACTOR 11 EXPRESSION 2014
  • Freier Susan M.
  • Monia Brett P.
  • Zhang Hong
  • Zhao Chenguang
  • Crosby Jeffrey R.
  • Siwkowski Andrew M.
RU2739594C2
MODULATION OF ANDROGEN RECEPTOR EXPRESSION 2013
  • Makleod Robert A.
  • Kim Yansu
  • Chzhou Tyanyuan
  • Frejer Syuzan M.
  • Set Punit P.
  • Suejzi Erik
  • Monya Brett P.
RU2670486C9
TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF 2013
  • Faghihi Mohammad Ali
  • Coito Carlos
RU2661104C2
OLIGONUCLEOTIDE CONJUGATES 2013
  • Albek Nanna
  • Khansen Khenrik Fryudenlunn
  • Kammler Syuzann
  • Ravn Yakob
  • Erum Khenrik
RU2653438C2
TREATING SIRTIUN 1 (SIRT1)-RELATED DISEASES BY INHIBITON OF NATURAL ANTISENSE TRANSCRIPT 2009
  • Kollard, Dzhozef
  • Khor'Kova Sherman, Ol'Ga
  • Kojto, Karlush
  • De Leon, Belinda
RU2551234C2
TREATMENT OF DISEASES ASSOCIATED WITH ERYTHROPOIETIN (EPO) BY NATURAL EPO ANTISENSE TRANSCRIPT INHIBITION 2009
  • Kollard Dzhozef
  • Khorkova Sherman Olga
RU2620970C2
METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS, DIRECTLY ACTING ON CONNECTIVE TISSUE GROWTH FACTOR (CTGF) 2012
  • Din Nikolas M.
  • Krochmel Linkoln
  • Khardi Gregori
  • Foulkes Dzh. Gordon
  • O`Donnell Najall
  • Yang Leroj
  • Dzheuell Mark
RU2608655C2
TREATMENT OF APOLIPOPROTEIN-A1 RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO APOLIPOPROTEIN-A1 2009
  • Kollard Dzhozef
  • Khorkova Olga
RU2604489C2

RU 2 377 301 C2

Authors

Freden Miriam

Khansen Jens Bo

Erum Khenrik

Vestergor Majken

Tru Sharlot Al'Behk

Dates

2009-12-27Published

2004-12-23Filed